Expert commentary: While EMPA-REG had robust reduction in the CV-death, all-cause death and hHF, there … endobj reports research grants and/or personal fees from AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline, Insulet Corp, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Medtronic, Merck & Co Inc, Population Health Research Institute, Roche Pharma, Sanofi, and Takeda. In accordance with the results from SUSTAIN 1–5 trials, 12. 2017 Apr;43 Suppl 1:2S3-2S12. endstream 34 0 obj 43 0 obj Adobe InDesign CS6 (Macintosh) endstream x�+� � | <>stream endobj 303. Please enable it to take advantage of the complete set of features! endstream Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration),4 is currently in development but not yet approved for the treatment of type 2 diabetes. Table 1: Summary of Key … application/pdf <>>>/BBox[0 0 567 756]/Length 83>>stream This site needs JavaScript to work properly. �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ 51 0 obj 8 0 obj Estimated HRs and associated CIs are from a Cox proportional hazards model with an interaction between treatment (semaglutide, placebo) and subgroups as fixed factors. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WH, Temelkova-Kurktschiev T; REWIND Trial Investigators. x��A xmp.id:F404C54D102068118083E4872A240A24 9 0 obj default He also reports grants and personal fees as a consultant and/or speaker from Amgen, AstraZeneca, Boehringer Ingelheim, Faes Farma, Fresenius, Janssen Pharmaceuticals, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire, and UCB. 2020 Jun 22;19(1):96. doi: 10.1186/s12933-020-01070-z. N Engl J Med. Sorli C ; Harashima SI ; Tsoukas GM ; et al. %PDF-1.3 endobj x�S�*�*T0T0 B�����id�����]���1D.� pa Liberia War Crimes: Inconsistent testimonies plague Massaquoi trial One witness said he narrowly escaped with others when Mr Massaquoi allegedly ordered his men to … endstream -, Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. 1 0 obj 54 0 obj received research grants to her institution and consulting fees from Novo Nordisk during the conduct of the study. Sustain XL All Natural.Energy Stamina & Extra-Strength Booster Trial Pack (4) Capsules. x��1�0�ݧ�#,��D�l����Р�VqZ�G� ��w:��A���m���!o��2�[Iϱ��p�>��8.��zR�)&���)g����iYup�ˋ�B_�| � x��1�0�ݧ�#,��D�l����Р�VqZ�G� ��w:��A���m���!o��2�[Iϱ��p�>��8.��zR�)&���)g����iYup�ˋ�B_�| � x��1�0�ݧ�#,��D�l����Р�VqZ�G� ��w:��A���m���!o��2�[Iϱ��p�>��8.��zR�)&���)g����iYup�ˋ�B_�| � Hertzel C Gerstein. endobj endobj Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Management of hyperglycemia in type 2 diabetes, 2018. x��1�0�ݧ�#,��D�l����Р�VqZ�G� ��w:��A���m���!o��2�[Iϱ��p�>��8.��zR�)&���)g����iYup�ˋ�B_�| � 2010;375:2215–2222. endobj 47 0 obj endobj <>>>/BBox[0 0 567 756]/Length 129>>stream 2018 Apr;6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X. endstream x�s x�+� � | 60 0 obj Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I. Diabetes Metab. 18 0 obj Epub 2019 Jan 4. endstream Would you like email updates of new search results? After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? x�S�*�*T0T0 B�����i�����U���)D*� 9V� 2018;2018(41):2669–2701. x��A x�S�*�*T0T0 B�����ih�����]��� D.� pa endstream Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. x�+� � | endstream 15 0 obj x��A <>stream ��w3T�PI�2T0 BC##=Cc#��\.���T��r׼��ļ��Ң����4�Ԕ��̼T͐,.�. Treatment differences in hospitalization for unstable angina or heart failure, and revascularization in SUSTAIN 6. Diabetes Care. ��w3T�PI�2T0 BC##=Cc#��\.���T��r׼��ļ��Ң����4�Ԕ��̼T͐,.�. Other aspects of the trial began to come into focus Monday as well. 2018 Dec;52(12):1224-1232. doi: 10.1177/1060028018784583. Only 2 left in stock - order soon. <>>>/BBox[0 0 567 756]/Length 129>>stream 2018 Jun 1;103(6):2291-2301. doi: 10.1210/jc.2018-00070. x�+� � | <>>>/BBox[0 0 567 756]/Length 112>>stream x��A endobj N Engl J Med. endstream �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ endobj Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. x�s Listing a study does not mean it has been evaluated by the U.S. Federal Government. -, American Diabetes Association Cardiovascular disease and risk management: standards of medical care in diabetes 2019. <>stream endstream x��1�0�ݧ�#,��D�l����Р�VqZ�G� ��w:��A���m���!o��2�[Iϱ��p�>��8.��zR�)&���)g����iYup�ˋ�B_�| � �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ Careers. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. endstream In subjects with a prior MI/stroke (. <>>>/BBox[0 0 567 756]/Length 112>>stream endstream Gastrointestinal adverse events in all treatment groups were more common among women than men, but rates of premature treatment discontinuation were similar for both genders. ��w3T�PI�2T0 BC##=Cc#��\.���T��r׼��ļ��Ң����4�Ԕ��̼T͐,.�. Time to MACE and its individual components (CV death, nonfatal MI, nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization (coronary and peripheral) were analyzed for all subgroups. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. ��w3T�PI�2T0 BC##=Cc#��\.���T��r׼��ļ��Ң����4�Ԕ��̼T͐,.�. Prevention and treatment information (HHS). Subjects were censored at their planned end-of-trial visit, last direct subject-site contact or all-cause death of the subject, whichever occurred first. 13 0 obj 3.9 out of 5 stars 65. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. 1: Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. x�s <>>>/BBox[0 0 567 756]/Length 83>>stream <>>>/BBox[0 0 567 756]/Length 83>>stream endobj Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. 2018 Jun 1;103(6):2291-2301. doi: 10.1210/jc.2018-00070. ��w3T�PI�2T0 BC##=Cc#��\.���T��r׼��ļ��Ң����4�Ԕ��̼T͐,.�. Without side effects !!! x�S�*�*T0T0 B�����id�����]���%D.� r�s The trial conducted with empagliflozin (EMPA-REG) found it to be superior in reducing major adverse cardiac events (MACE). 2: Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, … <>>>/BBox[0 0 567 756]/Length 112>>stream <>stream 37 0 obj He also reports research grants from GlaxoSmithKline and personal fees for advisory panels from Servier. �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ endobj 6 0 obj Adverse events by gender in SUSTAIN 6. <>stream doi: 10.2337/dc19-S010. endstream <>>>/BBox[0 0 567 756]/Length 83>>stream The effects of gender, age and baseline CV risk on outcomes are important considerations for further study. The Lagos State government and the NPA, last Tuesday, disclosed the commencement of a three-month trial on enforcement and compliance of the … SUSTAIN 9 is the second clinical trial to show that the concomitant use of GLP-1 receptor agonists and SGLT-2 inhibitors is effective and generally well tolerated in patients with type 2 diabetes. In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile. Additional analyses were performed for gender and age to investigate change from baseline in HbA1c and body weight, as well as tolerability. <>>>/BBox[0 0 567 756]/Length 83>>stream Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial J Clin Endocrinol Metab . x�S�*�*T0T0 B�����il�����]���D.� pa SUSTAIN-6 Investigators: ... or both. Results: <>>>/BBox[0 0 567 756]/Length 129>>stream 29 0 obj Background: <>>>/BBox[0 0 567 756]/Length 112>>stream doi: 10.1021/acs.jmedchem.5b00726. 19 0 obj With four straight days of gains, the blue-chip Dow has gained 3.6%. FOIA endstream 46 0 obj Trump’s impeachment trial already shows how far US democracy has been undermined. endstream <>>>/BBox[0 0 567 756]/Length 112>>stream endstream PubMed PMID: 27633186. 38 0 obj <>stream �]� endobj x��A <>stream E.J. The key CV outcome results are summarized in Table 1. endobj endobj endobj FILE - In this July 7, 2015, file photo, Commissioner Bruce Castor, a former Montgomery County, Pa., District Attorney, speaks during an interview with The Associated Press in Norristown, Pa. Former President Donald Trump stands trial before the Senate on an impeachment charge that accuses him of inciting the deadly Jan. 6 riot at the U.S. Capitol. <>stream Privacy, Help Cardiovasc Diabetol. endstream More Buying Choices $18.95 (2 new offers) Sustain Sport Performance Hydration Drink 20pk - Raspberry Lemonade. uuid:f61f1aa4-5b68-8e42-af8b-3aa255ca3149 <>>>/BBox[0 0 567 756]/Length 83>>stream 27 0 obj Diabetes Obes Metab. COVID-19 is an emerging, rapidly evolving situation. endobj <>>>/BBox[0 0 567 756]/Length 112>>stream xmp.did:86B3B2EAF996E6118529DC407F2F8C13 Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Outside the submitted work, I.H. endstream endstream Key Results. The SUSTAIN 7 trial investigated semaglutide in a different population to SUSTAIN 6, and excluded patients with pre-existing proliferative retinopathy and maculopathy requiring acute treatment. endobj 21 0 obj <>>>/BBox[0 0 567 756]/Length 83>>stream Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. <>stream 2021-03-09T03:28:03-08:00 adobe:docid:indd:d03427a0-e66b-11de-bd24-81ae6252b62b Subjects were grouped according to gender, age (50-65 years and > 65 years), and CV risk profile at baseline (prior myocardial infarction [MI] or stroke vs no prior MI or stroke, and established CV disease [CVD] vs CV risk factors alone, including subjects with chronic kidney disease). Trial registry Clinicaltrials.gov, Identifying number: NCT01720446, Date of registration: October 29, 2012. �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ endstream Diabetes Metab. adobe:docid:indd:d03427a0-e66b-11de-bd24-81ae6252b62b 4.6 out of 5 stars 58. endstream �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ The majority of subjects (60.7%) were male; 43% were > 65 years of age; 41.5% had a history of MI or stroke; and 76.8% had established CVD. from application/x-indesign to application/pdf Diabetes Care. <>>>/BBox[0 0 567 756]/Length 112>>stream ��w3T�PI�2T0 BC##=Cc#��\.���T��r׼��ļ��Ң����4�Ԕ��̼T͐,.�. J Med Chem. x�s ��w3T�PI�2T0 BC##=Cc#��\.���T��r׼��ļ��Ң����4�Ԕ��̼T͐,.�. American Diabetes Association Standards of medical care in diabetes 2018. endstream Compared with placebo, semaglutide reduced the risk of the first occurrence of MACE and each MACE component consistently across all subgroups (gender, age, and baseline CV risk profile). x�s �]� Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT �]� x�s My girlfriend noticed the difference and that's the test that matters most. �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ endobj x�+� � | 10 0 obj 2019;42(Suppl 1):S103–S123. 55 0 obj <>>>/BBox[0 0 567 756]/Length 112>>stream <>stream endobj <>stream Age; Baseline cardiovascular risk; Cardiovascular events; Cardiovascular outcome trial; Gender; SUSTAIN 6; Semaglutide; Type 2 diabetes. x�+� � | endobj endstream The Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6) examines the … endobj endobj endobj -, Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. 53 0 obj x�s The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. endstream Aims: SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent semaglutide dose (1.0mg) with the current most frequently prescribed liraglutide dose in Europe (1.2mg), reflecting clinical practice. <>stream 41 0 obj doi: 10.2337/dci18-0033. Outside of the submitted work, S.M. 2018;41(Suppl 1):S1–S135. �]� endobj x��A endstream 7 0 obj posted March 07, 2021 at 10:20 pm by Rey E. Requejo. The primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and in 146 of 1649 patients (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95; P<0.001 for noninferiority). 8600 Rockville Pike endobj Ferdinand KC, Botros FT, Atisso CM, Sager PT. Correspondence. endstream Alfayez OM, Almohammed OA, Alkhezi OS, Almutairi AR, Al Yami MS. Cardiovasc Diabetol. He has also received a research grant from Novo Nordisk and Boehringer Ingelheim. <>stream 56 0 obj endobj 57 0 obj <>stream endstream has received honoraria, teaching, and research sponsorship/grants from Abbott, AstraZeneca, Boehringer Ingelheim, Cellnovo, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-aventis, Cardiff University, Doctors.net, Elsevier, Onmedica, Omnia-Med, Medscape, All-Wales Medicines Strategy Group, National Institute for Health and Care Excellence (NICE) UK, and Glycosmedia. �]� endobj Regarding SUSTAIN-6 specifically, Dr Zinman said: "It's exciting to have another positive trial with respect to cardiovascular outcomes. <>>>/BBox[0 0 567 756]/Length 129>>stream 14 0 obj Clipboard, Search History, and several other advanced features are temporarily unavailable. Lancet. 2014. x��1�0�ݧ�#,��D�l����Р�VqZ�G� ��w:��A���m���!o��2�[Iϱ��p�>��8.��zR�)&���)g����iYup�ˋ�B_�| � 28 0 obj The median duration of exposure was 21.6 months in SUSTAIN 6 and 15.9 months in PIONEER 6. �0F�}N�/$vB݊v��\ �Ԥ$��oo��=��U���N��m�.�z����kI�F?b�(~Κ�.x:y\O0�!��_/��KX��H�i�܂�}U��^�s�5r�8�Y=���{+ x��A Outside of the submitted work, he has received grants and/or personal fees for advisory panels, speakers’ bureaus, and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. <>>>/BBox[0 0 567 756]/Length 112>>stream x�+� � | In both the CVOTs, trial completion rate was high (SUSTAIN 6: 97.6%; PIONEER 6: 99.7%) with vital status at end-of-trial known for 99.6% of patients in SUSTAIN 6 and 100% in PIONEER 6.